Opendata, web and dolomites

MePlat

Application of Cold Plasma Treatment for Antimicrobial Contact Lenses

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MePlat" data sheet

The following table provides information about the project.

Coordinator
MEDIPLASMA SRL 

Organization address
address: Piazza Sannazaro 71
city: NAPLES
postcode: 80122
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://web.mediplasma.it.spazioweb.it/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIPLASMA SRL IT (NAPLES) coordinator 50˙000.00

Map

 Project objective

While the market of contact lenses has evolved over the years, there still remains a need for contact lenses which inhibit or do not promote bacterial and microbial growth or adhesion to the surface of the lenses, while simultaneously being safe for the wearer. Our company has identified a business opportunity based on cold plasma technology which will revolutionise the contact lens market.. We have the ability to modify the surface properties of the contact lens, to increase resistance to the attachment of bacteria, making the contact lens safer. Through our technology we will also increase the comfort of the contact lens by adding an aqueous layer which will reduce the chances of the lens drying out. Based on successful clinical studies, the grafting of heparin to the surface of the contact lens, will decrease contact-lens-related morbidity. Heparin is a glycosaminoglycan and when exposed to a substrate (sulfur salt in our case), forms a molecular layer of water that prevents attachment of bacteria to the surface via adhesins . The possibility of grafting heparin directly to the surface of the contact lens will provide a much safer and more comfortable solution to contact lens users, one which lasts throughout the lifetime of the product.

With our process, we aim to disrupt the industry and drastically reduce incidents of severe eye infection resulting from inappropriate contact lens use and care. Furthermore, we aim to increase customer retention and reduce the dropout rate by making contact lenses more comfortable for the users, adding more relief and reducing instances of dryness and discomfort. The project proposal MePlat was submitted in September 2016 and received a score of 13.71, surpassing all thresholds (4.62 Impact, 4.52 excellence, 4.57 Implementation). We strongly believe in the potential of our project and after studying closely the ESR and discussing the project with our contact point, we are hereby putting forward a revised resubmission.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEPLAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEPLAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More